ShiraTronics
Private Company
Total funding raised: $25M
Overview
ShiraTronics is a clinical-stage neuromodulation company targeting the large and underserved chronic migraine market. Its core innovation is a fully implantable, head-based neurostimulation system that simultaneously targets both occipital and supraorbital nerve pathways. The company is currently advancing its lead program through the RELIEV-CM2 pivotal clinical trial in the United States and Australia, building on preliminary data from an earlier study. As a private, pre-revenue entity, its near-term success hinges on clinical trial outcomes and subsequent regulatory clearance.
Technology Platform
A fully implantable, head-based neuromodulation system designed for continuous, combinatorial stimulation of both occipital and supraorbital nerve pathways to treat chronic migraine.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
ShiraTronics competes in the migraine neuromodulation space with companies like Abbott (formerly St. Jude Medical) with occipital nerve stimulators and electroCore with non-invasive vagus nerve stimulators. Its primary competition, however, comes from the entrenched pharmaceutical industry, particularly the newer class of CGRP-inhibiting drugs. ShiraTronics' key differentiator is its fully implantable, dual-target, head-based system designed for continuous use.